

Adrenal

THERAPEUTIC TRIALS AND PROGNOSTIC MARKERS FOR ADRENAL DISEASES

Mortality and Specific Causes of Death in Endogenous Cushing's Syndrome: A Systematic Review, Meta-Analysis and Meta-Regression

Padiporn Limumpornpetch, Endocrinologist¹, Ann W. Morgan, MD, PhD¹, Ana Tigamescu, PhD¹, Mar Pujades-Rodriguez, MD, PhD¹, Victoria Nyawira Nyaga, PhD², Paul D. Baxter, PhD¹, Paul Michael Stewart, MD, FRCP¹.

¹University of Leeds, Leeds, United Kingdom, ²Unit of Cancer Epidemiology - Belgian Cancer Centre, Brussels, Belgium.

Background: Endogenous Cushing's syndrome (CS) refers to an inappropriate hypercortisolism usually caused by either Cushing's disease (CD) or adrenal CS (ACS). CS results in significant morbidity and excess mortality if untreated. Even in treated cases there is often a significant health burden. Due to the rarity of CS (incidence ~ 1/1M population), single cohort studies have insufficient power for reporting accurate mortality data. Only one previous systematic review and meta-analysis for CS has been reported that limited its scope to the inclusion of specific CD subgroup. **Aims:** To perform a meta-analysis and meta-regression analysis of all-cause and specific cause -mortality amongst patients with benign endogenous CS. **Methods:** The protocol was registered in PROSPERO (CRD42017067530). Searches were undertaken of PubMed, EMBASE, CINHAL, web of science and Cochrane Central from start until April 2019. The primary outcomes were proportion of mortality and SMR. The meta-analysis was done with STATA version 16.1 software. The I2 test, subgroup analysis and meta-regression statistics were used to assess heterogeneity among included studies. **Results:** A total of 11,527 articles, were retrieved. 87 articles with 100 study cohorts containing 17,276 CS patients reporting mortality were included. Fifty-three study cohorts reported Cushing's disease (CD) patients, 27 study cohorts reported for adrenal CS patients and 20 studies cohorts reported on both types of CS. The overall SMR of all type CS was 2.91 (95% CI 2.41–3.68) with I2 =40.3%. The SMR for CD was 3.27 (95% CI 2.33–4.21) with I2 = 55.6%. The SMR in ACS was 1.62 (95% CI 0.08–3.16) with I2 =0.0%. The overall proportion of death in CS was 0.05 (95% CI 0.03–0.06) with I2 =51.86%; in CD was 0.04 (95% CI 0.03–0.06) with I2 = 62.7% and in ACS 0.06 (95% CI 0.04–0.11) with I2 = 40.3 %. The proportion of death during the 30-day operative period was highest before 1991 at 0.07 and decreased to 0.03 in 1991–2000 to 0.01 in 2001–2010 and zero after 2011. The causes of death reported across 64 studies were cardiac causes (24.7%), infection (14.4%), cerebrovascular diseases (9.4%), malignancy (9.0%), thromboembolism (4.2%), active disease (2.9%), and adrenal insufficiency (2.7%). **Conclusion:** CS is associated with increase in overall mortality. Advances in operative techniques and care have decreased peri-operative mortality over a 20 year period. The causes of death highlight the need for aggressive management of cardiovascular risk, prevention of thrombo-embolism, infection control and a normalised cortisol level.

Adrenal

THERAPEUTIC TRIALS AND PROGNOSTIC MARKERS FOR ADRENAL DISEASES

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients

Massimo Terzolo, MD¹, Martin Fassnacht, MD², Paola Perotti, PhD¹, Rossella Libe, MD³, André Lacroix, MD⁴, Darko Kastelan, MD, PhD⁵, Harm Reinout Haak, MD, PhD⁶, Wiebke Arlt, MD⁷, Paola Loli, MD⁸, Bénédicte Decoudier, MD⁹, Helene Lasolle, MD¹⁰, Irina Bancos, MD¹¹, Marcus Quinkler, MD¹², Maria Candida Barisson Villares Frago, PhD, MD¹³, Letizia Canu, MD, PhD¹⁴, Soraya Puglisi, MD¹, Matthias Kroiss, MD², Tina Dusek, MD⁵, Isabelle Bourdeau, MD⁴, Eric Baudin, MD¹⁵, Paola Berchiolla, PhD¹⁶, Felix Beuschlein, MD¹⁷, Jerome Yves Bertherat, MD, PhD¹⁸, Alfredo Berruti, MD¹⁹.

¹University of Turin San Luigi Hospital, Orbassano, Italy, ²University of Würzburg, Würzburg, Germany, ³Rare cancer Network COMETE cancer, Hôpital Cochin, Paris, France, ⁴CHUM Université de Montreal, Montreal, QC, Canada, ⁵Department of Endocrinology University Hospital Zagreb, Zagreb, Croatia, ⁶Maxima Medisch Centrum, Eindhoven, Netherlands, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Niguarda Ca Granda Hospital, Milan, Italy, ⁹Centre Hospitalier Universitaire de Reims, Service d'Endocrinologie - Diabète – Nutrition, Reims, France, ¹⁰Hospices Civils de Lyon and University de Lyon, Lyon, France, ¹¹Mayo Clinic, Rochester, MN, USA, ¹²Endocrinology in Charlottenburg, Berlin, Germany, ¹³Serviço de Endocrinologia e Metabologia, ICESP, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy, ¹⁵Endocrine Oncology Gustave Roussy, Villejuif, France, ¹⁶Statistical Unit, Department of Clinical and Biological Sciences, University of Turin San Luigi Hospital, Orbassano, Italy, ¹⁷Department of Endocrinology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ¹⁸Hôpital Cochin, Paris, France, ¹⁹Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.

Background: The ESE-ENSAT guidelines on the management of adrenocortical carcinoma (ACC) suggest adjuvant mitotane for patients at high risk of recurrence following radical surgery. This indication has a limited evidence base, lacking results from randomized controlled trials. No suggestion for or against adjuvant mitotane in low-risk patients was given, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane treatment vs. observation in prolonging recurrence-free survival (RFS) in ACC patients at low-intermediate risk of recurrence.

Methods: The main inclusion criteria were: stage I-III ACC, R0 surgery, and Ki-67 ≤10%. Patients were randomly assigned 1:1 to adjuvant mitotane (MIT) or observation (OBS). The primary endpoint of the study was RFS. Patients who refused randomization were offered inclusion in the ADIUVO OBSERVATIONAL study. In this prospective, observational study, patients were managed as in the ADIUVO study. A total of 91 patients were enrolled in ADIUVO, 45 in the MIT and 46 in the OBS arm. Baseline characteristics of patients were perfectly matched between